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Is my vaccination programme working?   
  
Vaccine effectiveness: measuring vaccine 
protection in the field   
• Overview of traditional vaccine protection evaluation methods 
• How to assess vaccine protection during an outbreak 
• Overview of other vaccine effectiveness study designs 
 
Contents of presentation 
• Evaluation of FMD vaccines traditionally based on: 
 
1. Challenge studies 
• Control conditions and ensure adequate exposure 
• Small numbers and may not represent natural challenge 
 
2. Serological evaluation 
– Vaccine matching tests 
• Useful but imprecise test 
– Post vaccination SP antibody response – peak response and over 
entire intervaccination interval 
• Useful but what field virus are you concerned about and how does this relate 
to the test and vaccine antigen 
• Have you correlated your antibody response with protection against the virus 
of concern in a challenge study 
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Field study 
Cold chain 
Shelf life 
Batch variability 
Variable animal response 
Field protection: 
protection that counts 
Match with field virus 
Time since last vaccinated 
Number of doses in lifetime 
Level/duration of virus exposure 
• The percentage reduction in incidence in 
vaccinated compared to unvaccinated 
individuals under field conditions 
 
Vaccine effectiveness 
• The percentage reduction in incidence in 
vaccinated compared to unvaccinated 
individuals under field conditions 
 
• Incidence risk 
–  [percentage or proportion affected during defined 
period] – e.g. 0.01 or 1% 
• Incidence rate 
–  [number affected/sum of time at risk for all 
individuals] – 0.2 cases/animal–year at risk 
Vaccine effectiveness 
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2.  Are the animals being vaccinated (adequately)? 
 Vaccine coverage 
• What is the bigger problem in your country? 
– Vaccine coverage 
– Vaccine effectiveness 
– Both 
– Don’t know 
Vaccine failure or failure to vaccinate 
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Vaccine effectiveness - > observational study 
 (field study – program conditions) 
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                  VE =    90-30    =  0.666 = 66.6% 
90 
or 
              VE = 1 - 30 =  0.666 = 66.6% 
90 
VE 100% = complete protection with 0% incidence in vaccinated 
VE 0% = no protection – same incidence in vaccinated & unvaccinated 
At an outbreak 
80% of unvaccinated cattle had clinical FMD 
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a) 75%  b) 60%  c) 25% d) 40% 
Question 
VE =       Unvac incidence – Vac inc         x 100% 
                             Unvac inc 
At an outbreak 
80% of unvaccinated cattle had clinical FMD 
20% of vaccinated cattle had clinical FMD 
 
What is vaccine effectiveness? 
 
a) 75%  b) 60%  c) 25% d) 40% 
Question 
VE =       Unvac incidence – Vac inc         x 100% 
                             Unvac inc 
Protection against clinical disease 
Protec ion against infection (NSP if purified vaccine!) 
 or infectiousness 
• What if only farmers whose animals have a 
high risk [of exposure to FMD virus] 
vaccinate their animals? e.g. dealers, use 
common grazing??? 
 
• Will vaccine effectiveness increase or 
decrease? 
Pathogen exposure 
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high risk [of exposure to FMD virus] 
vaccinate their animals? e.g. dealers, use 
common grazing??? 
 
• Will vaccine effectiveness increase or 
decrease? 
Pathogen exposure 
This bias will decrease VE – vaccine may protect but 
vaccinated animals have a greater virus challenge 
than unvaccinated – unfair comparison 
• Age 
• Prior infection 
• Number of times previously vaccinated 
• Level of exposure [common or private grazing] 
• Herd size? 
But FMD risk is affected by other factors that 
affect susceptibility and exposure 
• Age 
• Prior infection 
• Number of times previously vaccinated 
• Level of exposure [common or private grazing] 
• Herd size? 
But FMD risk is affected by other factors that 
affect susceptibility and exposure 
• Age  
• Assess different age groups separately 
• Exclude <7 months – maternal immunity 
• Prior infection 
• Exclude village or exclude old cattle if outbreak a few years a go 
• Number of times previously vaccinated  
• Assess separately according to number of doses 
• Limitation - May not be able to adjust for both age & number of 
doses – closely correlated? 
• Level of exposure [common or private grazing] 
• Herd size? 
But FMD risk is affected by other factors that 
affect susceptibility and exposure 
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• Assess different age groups separately 
• Exclude <7 months – maternal immunity 
• Prior infection 
• Exclude village or exclude old cattle if outbreak a few years a go 
• Number of times previously vaccinated  
• Assess separately according to number of doses 
• Limitation - May not be able to adjust for both age & number of 
doses – closely correlated? 
• Level of exposure [common or private grazing] 
• Herd size? 
But FMD risk is affected by other factors that 
affect susceptibility and exposure 
Ideally - vaccinated and 
unvaccinated are similar in terms 
of confounders – in reality 
differences will exist that must 
be adjusted for through design 
and during analysis 
Incidence risk by age:  
Example 1 
Age Vaccinated Unvaccinated VE 
7-12 months 15% 60% 75% 
13-24 months 25% 85% 71% 
>24 months 5% 25% 80% 
Overall 20% 80% 75% 
In this example age makes little difference to VE 
So report crude VE unadjusted for age (75%) 
Incidence risk by age:  
Example 2 
Age Vaccinated Unvaccinated VE 
7-12 months 20% 30% 33% 
13-24 months 25% 100% 75% 
>24 months 10% 25% 60% 
Overall 15% 90% 83% 
Can still have unacceptable 
incidence in vaccinated even 
when good VE 
Incidence risk by age:  
Example 2 
Age Vaccinated Unvaccinated VE 
7-12 months 20% 30% 33% 
13-24 months 25% 100% 75% 
>24 months 10% 25% 60% 
Overall 15% 90% 83% 
Unvaccinated 13-24 
months probably 
over-represented in 
overall sample 
VE varies by age 
Report VE for each age group 
Mor  complex an lysis sometimes needed 
 
 
 – get weighted average using Mantel-Haenszel methods 
 www.winepi.net Programmed spreadsheet or stats software 
 
 – regression modelling [adjust for many factors at same time] 
 
Remember p values and confidence intervals! 
 
 
 
 
• What if no unvaccinated animals? 
• Just looking at incidence by number of 
doses is useful 
Simplest of all 
  
 
 
 
 
36 
“Incidence risk” versus “Number of lifetime doses” 
Farm 1 – Vaccine – Lyons, Kenya 
Incidence plateau among 
older animals… 
no vaccine effect! 
Lower incidence in 
youngstock… 
maternal protection? 
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“Incidence risk” versus “Number of lifetime doses” 
 
Farm 2 – Vaccine – Lyons, Kenya 
Maternal antibody? 
Incidence plateau… 
Declining incidence implies 
some vaccine effectiveness 
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40% incidence in multiply vaccinated  clearly reveals a 
problem…. 
• Potency?  
• Match? 
• Cold chain? 
 
Suboptimal schedules as well? 
 
 
Can have multiple reasons for poor VE! 
 
Possible reasons for incidence pattern on Farm 2 
Retrospective effectiveness – studies 
Turkey 2011/12 
 
1 
2, 4 
3 
 
• Four VILLAGE outbreak investigations: Asia-1  
 
 
 
Knight-Jones T.J., Bulut A.N., Gubbins S., Stark K.D., Pfeiffer D.U., Sumption K.J., Paton D.J. 2014 Retrospective evaluation 
of foot-and-mouth disease vaccine effectiveness in Turkey. Vaccine (32), 1848-1855.  
• Find outbreak of the right strain where the vaccine 
has been used 
• Timing: At or near the end of an outbreak 
• Time since vaccination is important 
• [too soon or too long after vaccination] 
Sampling-Retrospective cohort 
Sampling-Retrospective cohort 
1. Within a village – at end of outbreak: 
1. Select all or sample of affected households  
 [households with cases or NSP positive - known virus exposure] 
2. Random or evenly spaced in village 
3. Sample several villages affected by outbreak [need at least 200-400 
animals] 
4. Need vaccinated and unvaccinated animals for comparison 
 
2. Within a household: 
1. Collect details of all cattle >5 months [may exclude more during analysis] 
 
3. For each selected animal 
1. Ask owner about vaccination and FMD history 
 – cross-ref with written records 
2. Examine for clinical signs 
3. Assess infection history by serology (<30 months) 
Results 
Vaccine Investigation 
Unvaccinated Vaccinated Unadjusted  
Vaccine effectiveness 
(95% CI) FMD/Total 
Shamir 1 - Ardahan 19/47 (40%) 188/249 (76%) -87% (-140% to -40%) 
Sindh08 
2 - Afyon-1 64/127 (50%) 14/91 (15%) 73% (51% to 85%) 
3 – Denizli 55/68 (81%) 134/337 (40%) 51% (41% to 59%) 
4 - Afyon-2 71/124 (57%) 69/187 (37%) 36% (18% to 49%) 
Need to adjust for other confounding factors – age, husbandry, etc… 
Asia-1: Multivariable model 
Risk factor 
Vaccine effectiveness 
[95% CI] 
Recently Vaccinated 
Sindh-08 69%  [50% to 81%] 
Shamir -36% [-137% to 22%] 
Rate Ratio 
Avoid common grazing 0.2 [0.1-0.36] 
Age: Every month >15 months 0.98 [0.977-0.99] 
Herd size >30 0.25 [0.1 – 0.5] 
Random intercept: Village/Owner  
St dev of intercept =  
                           6 / 1.4 
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63%  [ 29% to 81%] protection against infection 
 
Results 
Vaccine Investigation 
Unvaccinated Vaccinated Unadjusted  
Vaccine effectiveness 
(95% CI) FMD/Total 
Shamir 1 - Ardahan 19/47 (40%) 188/249 (76%) -87% (-140% to -40%) 
Sindh08 
2 - Afyon-1 64/127 (50%) 14/91 (15%) 73% (51% to 85%) 
3 – Denizli 55/68 (81%) 134/337 (40%) 51% (41% to 59%) 
4 - Afyon-2 71/124 (57%) 69/187 (37%) 36% (18% to 49%) 
Few 
unvaccinated 
animals 
Wide confidence 
intervals 
Several investigations for one vaccine preferable 
Unvaccinated animals much 
younger - protected by 
maternal immunity – 
confounded VE 
But: Incidence in 
vaccinated alone can be 
informative 
Poor vaccine match: 
r1-value < 0.3 
  
 
1. Protection from Asia-1 field strain by standard potency 
Asia-1 Shamir vaccine was not detected in this outbreak 
 
2. Reasonable protection from Asia-1 field strain by Asia-1 
Sindh08 [TUR 11] vaccine 
• Vaccine effectiveness:  
“Give it a go!” 
• Retrospective outbreak investigation is 
quick and simple 
• Useful answers 
• Gets you into the field 
– Learn things that nobody reports to HQ 
 
Conclusions 
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FMD vaccine evaluation 
Challenge 
studies 
in vitro 
matching 
assays 
Post-
vaccination 
serology 
Vaccine 
effectiveness 
Other… 
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FMD vaccine evaluation 
What post vaccination monitoring do you do? 
• Vaccine effectiveness 
• Batch serology under controlled conditions 
• Post-vaccination serology in the field 
• Vaccine matching tests 
• Challenge studies 
• Evaluation of different dosing regimes 
• Vaccine coverage 
• Other? 
• Retrospective outbreak investigation 
– Rely on farmer & vet recollection and records 
– Are outbreaks non-representative cases of vaccine 
failure? 
• Prospective  
– can create own vaccine groups and see what happens 
– Cohort, randomised trial 
– But what if no cases?  
– & prospective needs much more resources 
• Money & expertise & time 
• If free zone monitor post-vaccination serology 
VE designs 

Any questions? 
  Thank you for your attention! 
